^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FDFT1 rearrangement + FGFR2 rearrangement

    i
    Other names: FDFT1, Farnesyl-Diphosphate Farnesyltransferase 1, SQS, Squalene Synthase, FPP:FPP Farnesyltransferase, SS, Farnesyl-Diphosphate Farnesyltransferase, Presqualene-Di-Diphosphate Synthase, Squalene Synthetase, DGPT, ERG9, SQSD, FGFR2, BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25, Fibroblast growth factor receptor 2
    Entrez ID:
    2263; 2222
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over2years
    FDFT1/FGFR2 rearrangement: A newly identified anlotinib-sensitive FGFR2 variant in cholangiocarcinoma. (PubMed, Cancer Treat Res Commun)
    After treatment, the tumor size continued to shrink, and no significant adverse effects were reported. The finding suggested that anlotinib may be effective in patients with FDFT1/FGFR2 rearrangement and could serve as a novel treatment option for affected patients in future.
    Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2) • FDFT1 (Farnesyl-Diphosphate Farnesyltransferase 1)
    |
    FGFR2 fusion • FGFR2 rearrangement • FDFT1 rearrangement + FGFR2 rearrangement
    |
    Focus V (anlotinib)